

Francesco Merli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2864209/publications.pdf>

Version: 2024-02-01

117
papers

6,887
citations

61945

43
h-index

60583

81
g-index

117
all docs

117
docs citations

117
times ranked

6201
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Interim 2-[¹⁸ F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3746-3752.	0.8	799
2	Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. <i>Journal of Clinical Oncology</i> , 2009, 27, 4555-4562.	0.8	613
3	Early Positron Emission Tomography Response—Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1786-1794.	0.8	397
4	ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 805-811.	0.8	256
5	R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLLO5 Trial Conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 1506-1513.	0.8	223
6	Splenic marginal zone lymphoma: a prognostic model for clinical use. <i>Blood</i> , 2006, 107, 4643-4649.	0.6	217
7	The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. <i>Haematologica</i> , 2006, 91, 475-81.	1.7	213
8	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2766-2772.	0.8	190
9	ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2005, 23, 9198-9207.	0.8	167
10	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2019, 394, 2271-2281.	6.3	155
11	Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1113-1122.	3.3	152
12	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015, 126, 950-956.	0.6	138
13	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014, 25, 1404-1410.	0.6	133
14	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLLO5 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013, 24, 2108-2112.	0.6	124
15	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. <i>British Journal of Haematology</i> , 2012, 156, 346-353.	1.2	122
16	Long-Term Results of the FOLLO5 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 689-696.	0.8	107
17	Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. <i>Lancet Oncology, The</i> , 2014, 15, 343-352.	5.1	100
18	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2017, 18, 1076-1088.	5.1	100

#	ARTICLE	IF	CITATIONS
19	Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. <i>Annals of Hematology</i> , 2007, 86, 897-903.	0.8	98
20	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016, 34, 1175-1181.	0.8	94
21	Resveratrol-mediated apoptosis of Hodgkin lymphoma cells involves SIRT1 inhibition and FOXO3a hyperacetylation. <i>International Journal of Cancer</i> , 2013, 132, 1013-1021.	2.3	93
22	Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e272-e282.	2.2	91
23	Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3293-3299.	0.8	90
24	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> , 2012, 53, 581-588.	0.6	74
25	Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study. <i>Annals of Hematology</i> , 2012, 91, 931-939.	0.8	74
26	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021, 39, 1214-1222.	0.8	74
27	Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2014, 55, 38-43.	0.6	72
28	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
29	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014, 25, 442-447.	0.6	67
30	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , 2016, 3, e467-e479.	2.2	63
31	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017, 8, 79073-79086.	0.8	63
32	Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. <i>Leukemia</i> , 2015, 29, 1344-1349.	3.3	62
33	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017, 92, 37-41.	2.0	62
34	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	2.0	61
35	Image-Aided Estimate of Tumor Burden in Hodgkin's Disease: Evidence of Its Primary Prognostic Importance. <i>Journal of Clinical Oncology</i> , 2001, 19, 1388-1394.	0.8	59
36	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). <i>Journal of Clinical Oncology</i> , 2018, 36, 2593-2602.	0.8	59

#	ARTICLE	IF	CITATIONS
37	Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. <i>Cancer</i> , 2007, 109, 2077-2082.	2.0	50
38	The prognostic value of positron emission tomography performed after two courses (^{INTERIM}PET) of standard therapy on treatment outcome in early stage ^Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015, 90, 499-503.	2.0	49
39	Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients. <i>PLoS ONE</i> , 2013, 8, e74326.	1.1	48
40	Comparison of prognostic models in patients with advanced Hodgkin disease. <i>Cancer</i> , 2001, 91, 1467-1478.	2.0	47
41	The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. <i>Cancer</i> , 2004, 101, 1824-1834.	2.0	47
42	Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2011, 29, 4227-4233.	0.8	47
43	Involved-Site Image-Guided Intensity Modulated Versus 3D Conformal Radiation Therapy in Early Stage Supradiaphragmatic Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 370-375.	0.4	46
44	Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the <i>Fondazione Italiana Linfomi</i>. <i>Haematologica</i> , 2018, 103, 1345-1350.	1.7	45
45	Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1867-1872.	0.6	43
46	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléculas Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 53-57.	0.6	42
47	Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. <i>Cancer</i> , 2007, 110, 121-128.	2.0	41
48	Prognostic relevance of serum λ 2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. <i>Haematologica</i> , 2007, 92, 1482-1488.	1.7	38
49	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , 2018, 36, 68-75.	0.8	34
50	Reduced intensity ^{VEPEMB} regimen compared with standard ^{ABVD} in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (^{FIL}). <i>British Journal of Haematology</i> , 2016, 172, 879-888.	1.2	29
51	Autoimmune Thyroid Dysfunctions in Hematologic Malignancies Treated with Alpha-Interferon. <i>Acta Haematologica</i> , 1995, 93, 31-35.	0.7	28
52	Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma. <i>Cancer</i> , 2003, 98, 2393-2401.	2.0	28
53	Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1077-1083.	0.4	28
54	Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. <i>Bone Marrow Transplantation</i> , 2018, 53, 461-473.	1.3	28

#	ARTICLE	IF	CITATIONS
55	Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 136-140.	2.5	27
56	Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study. <i>Leukemia and Lymphoma</i> , 2015, 56, 3281-3287.	0.6	25
57	Transplant results in adults with Fanconi anaemia. <i>British Journal of Haematology</i> , 2018, 180, 100-109.	1.2	25
58	The Role of Anthracyclines in Combination Chemotherapy for the Treatment of Follicular Lymphoma: Retrospective Study of the Intergruppo Italiano Linfomi on 761 Cases. <i>Leukemia and Lymphoma</i> , 2003, 44, 1911-1917.	0.6	24
59	Treatment of Indolent B-Cell Nonfollicular Lymphomas: Final Results of the LL01 Randomized Trial of the Gruppo Italiano per lo Studio dei Linfomi. <i>Journal of Clinical Oncology</i> , 2003, 21, 1459-1465.	0.8	23
60	Methylation changes of SIRT1, KLF4, DAPK1 and SPG20 in B-lymphocytes derived from follicular and diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2017, 57, 89-96.	0.4	23
61	Erythema nodosum and Hodgkin's disease. <i>Clinical and Experimental Dermatology</i> , 2001, 26, 408-411.	0.6	22
62	Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas. <i>Cancer</i> , 2012, 118, 3954-3961.	2.0	21
63	Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach. <i>Cancers</i> , 2021, 13, 3316.	1.7	21
64	The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Bone Marrow Transplantation</i> , 2006, 37, 283-288.	1.3	20
65	Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 367-373.	0.6	20
66	Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interim PET-negative classical Hodgkin Lymphoma patients: A radio-genomic study. <i>Hematological Oncology</i> , 2022, 40, 645-657.	0.8	19
67	ProMECE-CytaBOM vs MACOP-B in Advanced Aggressive Non-Hodgkin's Lymphoma: Long Term Results of a Multicenter Study of the Italian Lymphoma Study Group (GISL). <i>Leukemia and Lymphoma</i> , 1995, 17, 313-320.	0.6	18
68	Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 404-408.	0.2	18
69	Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1042-1055.	2.9	18
70	EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1). <i>Cancers</i> , 2021, 13, 4578.	1.7	18
71	Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. <i>Hematological Oncology</i> , 2012, 30, 194-199.	0.8	16
72	EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2). <i>Cancers</i> , 2021, 13, 4527.	1.7	14

#	ARTICLE	IF	CITATIONS
73	Caregivers of Patients with Hematological Malignancies within Home Care: A Phenomenological Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 4036.	1.2	13
74	The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK ⁺ anaplastic large cell lymphoma by regulating the DNA helicase HELLS. <i>Leukemia</i> , 2020, 34, 2964-2980.	3.3	13
75	Post-ABVD/pre-radiotherapy ¹⁸ F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. <i>British Journal of Radiology</i> , 2016, 89, 20150983.	1.0	12
76	Brentuximab vedotin followed by ABVD + ⁶⁰ Co radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. <i>Haematologica</i> , 2016, 101, e139-e141.	1.7	12
77	Chemoresistance As a Function of the Pretherapy Tumor Burden and the Chemotherapy Regimen Administered: Differences Observed With 2 Current Chemotherapy Regimens for Advanced Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 396-402.	0.2	11
78	A Gene Expression ¹ -based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients. <i>Clinical Cancer Research</i> , 2020, 26, 373-383.	3.2	11
79	Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Annals of Hematology</i> , 2011, 90, 323-330.	0.8	10
80	Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy. <i>Hematological Oncology</i> , 2013, 31, 151-155.	0.8	10
81	Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. <i>Hematological Oncology</i> , 2022, 40, 32-40.	0.8	10
82	Response-Guided ABVD Chemotherapy plus Involved-Field Radiation Therapy for Intermediate-Stage Hodgkin Lymphoma in the Pre ¹⁸ F-Positron Emission Tomography Era: A Gruppo Italiano Studio Linfomi (GISL) Prospective Trial. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 138-144.	1.4	9
83	Prospective Study of Indolent Non-follicular Non-Hodgkin's Lymphoma: Validation of Gruppo Italiano Per Lo Studio Dei Linfomi (GISL) Prognostic Criteria for Watch and Wait Policy. <i>Leukemia and Lymphoma</i> , 2002, 43, 1933-1938.	0.6	8
84	The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. <i>European Journal of Haematology</i> , 2006, 76, 217-229.	1.1	8
85	Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters. <i>Oncology Reports</i> , 2012, 28, 815-820.	1.2	8
86	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2019, 60, 2890-2898.	0.6	8
87	KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells. <i>Oncology Reports</i> , 2021, 47, .	1.2	8
88	T-cell receptor genes expression in B-cell leukaemias. <i>British Journal of Haematology</i> , 1989, 72, 343-349.	1.2	7
89	LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013037.	0.5	7
90	B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016, 57, 2375-2381.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Aggressive lymphomas of the elderly: the <scp>DEVEC</scp> metronomic chemotherapy schedule fits the unfit. <i>British Journal of Haematology</i> , 2018, 183, 819-822.	1.2	7
92	Bleomycin, Epidoxorubicin, Cyclophosphamide, Vincristine and Prednisone (BACOP) in Patients with Follicular Non-Hodgkin's Lymphoma: Results of a Prospective, Multicenter Study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). <i>Leukemia and Lymphoma</i> , 2002, 43, 1795-1801.	0.6	6
93	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , 2015, 100, 517-524.	1.7	6
94	Gene expression profile unveils diverse biological effect of serum vitamin D in Hodgkin's and diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2021, 39, 205-214.	0.8	6
95	The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL). <i>Annals of Oncology</i> , 2006, 17, 676-682.	0.6	5
96	Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. <i>Oncology Reports</i> , 2009, 21, 1029-35.	1.2	5
97	The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis. <i>Leukemia and Lymphoma</i> , 2011, 52, 148-149.	0.6	5
98	Hodgkin's lymphoma: post- autologous transplantation consolidation therapy. <i>Acta Biomedica</i> , 2020, 91, 23-29.	0.2	5
99	The Early- and Intermediate-Term Toxicity to Primitive Hematopoietic Progenitor Cells of Three Chemotherapy Regimens for Advanced Hodgkin Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 425-429.	1.4	4
100	Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy. <i>Leukemia and Lymphoma</i> , 2011, 52, 1689-1696.	0.6	4
101	Non-Pegylated Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study. <i>Blood</i> , 2007, 110, 1293-1293.	0.6	4
102	Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma: results from the hd2000 GISL trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 406-410.	0.6	3
103	Integrating Oncogeriatric Tools into the Management of Chronic Lymphocytic Leukemia: Current State of the Art and Challenges for the Future. <i>Current Oncology Reports</i> , 2015, 17, 31.	1.8	3
104	Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-9.	1.0	3
105	EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 3). <i>Cancers</i> , 2021, 13, 6021.	1.7	3
106	Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls. <i>Current Oncology</i> , 2022, 29, 956-968.	0.9	3
107	Stem cell transplantation patients receiving a novel oral care protocol for oral mucositis prevention and treatment: patient-reported outcomes and quality of life. <i>Supportive Care in Cancer</i> , 2022, 30, 6317-6325.	1.0	3
108	Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. <i>Leukemia and Lymphoma</i> , 2010, 51, 422-429.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Increase in clusterin forms part of the stress response in Hodgkin's lymphoma. International Journal of Oncology, 2011, 38, 677-84.	1.4	2
110	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. Leukemia and Lymphoma, 2016, 57, 2677-2680.	0.6	2
111	Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients. Revista Brasileira De Hematologia E Hemoterapia, 2016, 38, 247-251.	0.7	2
112	Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. British Journal of Haematology, 2021, 192, 1011-1014.	1.2	2
113	Impact of PET on the Radiation Treatment of Hodgkins Lymphoma. Current Radiopharmaceuticals, 2009, 2, 169-174.	0.3	2
114	Reply to T.P. Vassilakopoulos et al. Journal of Clinical Oncology, 2016, 34, 3585-3586.	0.8	1
115	Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. Annals of Hematology, 2021, 100, 2547-2556.	0.8	1
116	R-CHOP vs R-MiniCEOP in Elderly Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) Prospectively Selected by a Multidimensional Evaluation Scale: Preliminary Results of a Randomized Study Performed by Intergruppo Italiano Linfomi (IIL).. Blood, 2007, 110, 3429-3429.	0.6	1
117	Front-Line Chemo-Immunotherapy Rituximab-FC + Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Update of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324).. Blood, 2009, 114, 2686-2686.	0.6	1